Abstract:Recent evidence indicates that measures from cerebrospinal fluid, MRI scans and cognitive testing obtained from cognitively normal individuals can be used to predict likelihood of progression to mild cognitive impairment several years later, for groups of individuals. However, it remains unclear whether these measures are useful for predicting likelihood of progression for an individual. The increasing focus on early intervention in clinical trials for Alzheimer's disease emphasizes the importance of improving the ability to identify which cognitively normal individuals are more likely to progress over time, thus allowing researchers to efficiently screen participants, as well as determine the efficacy of any treatment intervention. The goal of this study was to determine which measures, obtained when individuals were cognitively normal, predict on an individual basis, the onset of clinical symptoms associated with a diagnosis of mild cognitive impairment due to Alzheimer's disease. Cognitively normal participants (n = 224, mean baseline age = 57 years) were evaluated with a range of measures, including: cerebrospinal fluid amyloid-β and phosphorylated-tau, hippocampal and entorhinal cortex volume, cognitive tests scores and APOE genotype. They were then followed to determine which individuals developed mild cognitive impairment over time (mean follow-up = 11 years). The primary outcome was progression from normal cognition to the onset of clinical symptoms of mild cognitive impairment due to Alzheimer's disease at 5 years post-baseline. Time-dependent receiver operating characteristic analyses examined the sensitivity and specificity of individual measures, and combinations of measures, as predictors of the outcome. Six measures, in combination, were the most parsimonious predictors of transition to mild cognitive impairment 5 years after baseline (area under the curve = 0.85; sensitivity = 0.80, specificity = 0.75). The addition of variables from each domain significantly improved the accuracy of prediction. The incremental accuracy of prediction achieved by adding individual measures or sets of measures successively to one another was also examined, as might be done when enrolling individuals in a clinical trial. The results indicate that biomarkers obtained when individuals are cognitively normal can be used to predict which individuals are likely to develop clinical symptoms at 5 years post-baseline. As a number of the measures included in the study could also be used as subject selection criteria in a clinical trial, the findings also provide information about measures that would be useful for screening in a clinical trial aimed at individuals with preclinical Alzheimer's disease.

Trajectories of Cognitive Decline in Different Domains Prior to AD onset in Persons with Mild Cognitive Impairment

Longitudinal Trajectories of General Cognitive and Daily Functions in Data-Driven Subtypes of MCI: a Longitudinal Cohort Analysis of Older Adults

Longitudinal trajectory effects of different MCI subtypes on general cognitive and daily functions in a population-based cohort of older adults

[O1–12–02]: PROGRESSION FROM PRECLINICAL AD TO MCI OVER A DECADE: COGNITIVE AND BRAIN IMAGING TRAJECTORIES

Trajectories of cognitive function and their determinants in older people: 12 years of follow-up in the Chinese Longitudinal Healthy Longevity Survey

A COMPUTATIONAL MONTE CARLO SIMULATION STRATEGY TO COMPARE THE ONSET OF DIFFERENT BIOMARKER AND COGNITIVE CHANGES

Uncovering Heterogeneous Cognitive Trajectories in Mild Cognitive Impairment: a Data-Driven Approach

Executive Functioning and Processing Speed as Predictors of Global Cognitive Decline in Alzheimer Disease

Distinct Atrophy Pattern of Hippocampal Subfields in Patients with Progressive and Stable Mild Cognitive Impairment: A Longitudinal MRI Study

Longitudinal analysis of abnormal domains comprising mild cognitive impairment (MCI) during aging.

New Trajectory of Clinical and Biomarker Changes in Sporadic Alzheimer's Disease.

Biomarkers for predicting cognitive decline in those with normal cognition.

Cognitive Decline in Patients with Alzheimer's Disease and Its Related Factors in a Memory Clinic Setting, Shanghai, China.

Trajectories of Age-Related Cognitive Decline and Potential Associated Factors of Cognitive Function in Senior Citizens of Beijing.

Early Microstructure Changes of White Matter Fiber Bundles in Patients with Amnestic Mild Cognitive Impairment Predicts Progression of Mild Cognitive Impairment to Alzheimer's Disease

Predicting Cognitive Decline in Amyloid-Positive Patients With Mild Cognitive Impairment or Mild Dementia

Mapping Cerebral Atrophic Trajectory from Amnestic Mild Cognitive Impairment to Alzheimer's Disease.

Estimating Dementia Onset: AT(N) Profiles and Predictive Modeling in Mild Cognitive Impairment Patients

Progression from Subjective Cognitive Decline to Mild Cognitive Impairment or Dementia: The Role of Baseline Cognitive Performance

Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years

Differential Cognitive Deterioration in Dementia: A Two Year Longitudinal Study